CCEL — Cryo-Cell International Income Statement
0.000.00%
Last trade - 00:00
- $72.13m
- $79.71m
- $31.34m
- 76
- 23
- 89
- 66
2019 November 30th | 2020 November 30th | C2021 November 30th | 2022 November 30th | 2023 November 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 31.8 | 31.1 | 28.9 | 30.3 | 31.3 |
Cost of Revenue | |||||
Gross Profit | 21.8 | 21.5 | 19.9 | 21.5 | 22.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 26.8 | 24.6 | 24.9 | 26.3 | 43.6 |
Operating Profit | 5.06 | 6.59 | 4.02 | 4.02 | -12.3 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 3.39 | 5.04 | 2.61 | 3.32 | -13.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | 2.29 | 3.62 | 2.08 | 2.77 | -9.52 |
Net Income Before Extraordinary Items | |||||
Net Income | 2.29 | 3.62 | 2.08 | 2.77 | -9.52 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 2.29 | 3.62 | 2.08 | 2.77 | -9.52 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.46 | 0.653 | 0.362 | 0.287 | 0.171 |
Special Dividends per Share |